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TRAIL Receptors 1 (DR4) and 2 (DR5) Signal
FADD-Dependent Apoptosis and Activate NF-kB
suggesting that strong regulatory mechanisms control
TRAIL receptor signals. TRAIL-R3 (DcR1/TRID) (Pan et
al., 1997a; Schneider et al., 1997b; Sheridan et al., 1997),
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others have recently characterized a family of viral andBIL Research Center
Chemin des Boveresses 155 mammalian proteins called FLICE-inhibitory proteins, or
FLIPs (I-FLICE/FLAME/CASPER/CASH), which interfereCH-1066 Epalinges
Switzerland with death receptor signaling pathways by binding to
FADD and FLICE (Bertin et al., 1997; Hu et al., 1997a,
1997b; Irmler et al., 1997; Shu et al., 1997; Srinivasula
et al., 1997; Thome et al., 1997). FLIPs block TRAILSummary
receptor±mediated death signals even though it has
been reported that TRAIL receptor signals are indepen-TRAIL induces apoptosis through two closely related
dent of FADD (Marsters et al., 1996a; Pan et al., 1997a,receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5). Here
1997b; Sheridan et al., 1997). We therefore studied thewe show that TRAIL-R1 can associate with TRAIL-R2,
signaling pathways triggered by the two TRAIL recep-suggesting that TRAIL may signal through heterore-
tors in more detail and report that in several cell linesceptor signaling complexes. Both TRAIL receptors
tested, FADD appears to be implicated in TRAIL signalbind the adaptor molecules FADD and TRADD, and
transmission.both deathsignals are interrupted by a dominant nega-
tive form of FADD and by the FLICE-inhibitory protein
Results and DiscussionFLIP. The recruitment of TRADD may explain the po-
tent activation of NF-kB observed by TRAIL receptors.
The Cytoplasmic Domains of TRAIL-R1 andThus, TRAIL receptors can signal both death and gene
TRAIL-R2 Form Heteroaggregatestranscription, functions reminiscent of those of TNFR1
Death receptors typically initiate signaling through li-and TRAMP, two other members of the death receptor
gand-induced homotrimerization. However, the highfamily.
overall structural homology between TRAIL-R1 and
TRAIL-R2 led us to examine whether apoptosis inducedIntroduction
by TRAIL could be transmitted via heterocomplexes of
the two closely related receptors. Expression vectorsSome members of the tumor necrosis factor (TNF)
coding for the cytoplasmic regions of TRAIL-R1 andreceptor family (Smith et al., 1994; Nagata, 1997) effi-
TRAIL-R2 carrying two distinct tag epitopes (Myc orciently transmit death signals via a cytoplasmic motif
Flag) were cotransfected into 293T cells. Figure 1 showscalled the death domain. To date, five such death recep-
that the cytoplasmic portion of TRAIL-R2 forms homo-tors have been analyzed: Fas (Dhein et al., 1995; Nagata,
aggregates but, in addition, also coprecipitates with the1997), TNF receptor 1 (TNFR1) (Tartaglia et al., 1993),
cytoplasmic portion of TRAIL-R1. In contrast, we de-TRAMP (wsl/Apo-3/DR3) (Kitson et al., 1996; Marsters
tected no association of the TRAIL receptors with theet al., 1996b;Yu et al., 1996; Bodmer et al., 1997), TRAIL-
cytoplasmic domain of Fas. Thus, it is possible thatR1 (DR4) (Pan et al., 1997b), and TRAIL-R2 (DR5) (Pan
TRAIL can bind either to a TRAIL-R1 trimer or to a TRAIL-et al., 1997a; Schneider et al., 1997b; Sheridan et al.,
R2 trimer, or to a combination of both receptors. The1997). The best-studied death signaling pathway is the
mixed receptor complexes may differ from TRAIL-R1one triggered by Fas ligand (FasL). FasL induces Fas
and TRAIL-R2 in their ligand-binding affinity or may re-clustering, followed by the binding of FADD to the recep-
cruit distinct intracellular adaptor proteins, possiblytor's death domain (Boldin et al., 1995; Chinnaiyan et
leading to the activation of specific signaling pathway(s).al., 1995; Kischkel et al., 1995). FADD then recruits the
caspase FLICE (MACH/caspase 8), facilitating the con-
nection from death receptors to caspases (Nicholson TRAIL-R1 and TRAIL-R2 Signal
and Thornberry, 1997). Apoptosis via FADD
TRAIL-R1 and TRAIL-R2 are the most recently identi- Both TRAIL-R1 and TRAIL-R2 efficiently induce apoptosis
fied death receptors. Their ligand TRAIL shows a broad (Pan et al., 1997a; Schneider et al., 1997b; Sheridan et
tissue distribution (Wiley et al., 1995) and like FasL, in- al., 1997). When 293T cells were transfected with equal
duces rapid apoptosis of various cell lines (Wiley et al., quantities of TRAIL-R1 or TRAIL-R2 respectively, a sim-
1995; Marsters et al., 1996a; Pitti et al., 1996). In contrast ilar extent of DNA degradation was observed (Figure
to FasL, however, TRAIL is not cytotoxic to tissues de- 2A). In contrast, overexpression of TRAIL-R3 did not
spite the widespread expression of TRAIL-R1 and -R2, induce cytotoxic effects (Figure 2A). To define the pro-
teins involved in TRAIL receptor signaling, 293T cells
were cotransfected with known inhibitors of the Fas-³To whom correspondence should be addressed (e-mail: jurg.
tschopp@ib.unil.ch). signaling pathway. Viral E8-FLIP and the long form of
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of the Flag-tagged TRAIL receptors revealed that FADD
associated with both TRAIL-R1 and TRAIL-R2 (Figure
3A), although the association was weaker than that ob-
served in parallel experiments using the Flag-tagged
cytoplasmic region of Fas (data not shown). In addition
to FADD, TRADD was detected in these immunoprecipi-
tates. However, TRADD binding was not observed in
the absence of coexpressed FADD, indicating that the
association of TRAIL-R1 and TRAIL-R2 with TRADD may
be mediated by FADD or may be dependent on the
presence of FADD in the signaling complex. Similar re-
sults were obtained when the association of full-length
TRAIL-R1 with FADD and TRADD was investigated (Fig-
ure 3B).
TRAIL-R1 and TRAIL-R2 Activate NF-kB
TRADD is an essential adaptor protein in the signal cas-
Figure 1. Association of TRAIL-R1 with TRAIL-R2 cade of TNFR1 and TRAMP, leading to the activation of
(Top) Immunoprecipitation of cell extracts from 293T cells, trans- the transcription factor NF-kB. The presence of TRADD
fected with expression vectors for the cytoplasmic segments of
in the signaling complex of the two TRAIL receptorsTRAIL-R1 and TRAIL-R2, was performed using an anti-Flag antibody
prompted us to assay NF-kB activity in cells transiently(precipitating Flag-TRAIL-R1 and Flag-TRAIL-R2, respectively).
transfected with a TNF promoter±derived NF-kB±lucif-Samples were analyzed for coprecipitating Myc-TRAIL-R2 or Myc-
Fas by Western blotting using anti-Myc antibodies. IP, immunopre- erase reporter gene together with increasing amounts of
cipitating. TRAIL-R1 and TRAIL-R2 expression vectors. Expression
(Middle and bottom) The expression levels of Flag-TRAIL-R1, Flag- of both TRAIL receptors strongly induced the activity of
TRAIL-R2, Myc-TRAIL-R2, and Myc-Fas in the corresponding cell
the reporter gene in a dose-dependent fashion (Figureextracts.
4). An increase in luciferase activity of up to 10-fold
was measured, comparable to levels induced by TRAMP
(Bodmer et al., 1997).cellular FLIP (FLIPL, which blocks FLICE recruitment and
activation) (Irmler et al., 1997; Thome et al., 1997) and Several lines of evidence indicate that FADD plays an
essential role in the death-inducing signaling complexa FADD dominant negative version of the protein (FADD-
DN, lacking the death effector domain) all reduced of TRAIL receptors. First, FADD-DN inhibits TRAIL-
induced cell death in three different cell lines: BJAB,apoptosis mediated by both TRAIL-R1 and TRAIL-R2
(Figure 2A). We conclude that the apoptotic signaling 293T, and CV-1 (Walczak et al., 1997); second, Jurkat cell
lines expressing FLIP of viral or cellular origin becomepathways of the two receptors are similar and involve
the intracellular proteins FADD and FLICE (caspase 8 resistant to TRAIL-mediated apoptosis (Irmler et al.,
1997; Thome et al., 1997); and third, FADD coimmuno-or caspase 10).
To corroborate our findings, we investigated signaling precipitates with TRAIL-R1 and TRAIL-R2. Our results
are in agreement with a report published while thisin cells that had been stably transfected with TRAIL-R1
(Figure 2B). In contrast to the parental cell line, which manuscript was under revision (Walczak et al., 1997) but
do not support previous findings that TRAIL-R1 doesshows little sensitivity to TRAIL despite the presence
of TRAIL-R2 mRNA (Figure 2C), TRAIL-R1±transfected not associate with FADD (Marsters et al., 1996a; Pan et
al., 1997a, 1997b; Sheridan et al., 1997). This discrep-293T cells (Figure 2C) are susceptible to TRAIL. When
these cells weretransfected with a FADD-DNexpression ancy is probably due to differences in the experimental
conditions used.vector, cells no longer responded to TRAIL, indicating
that TRAIL-R1 signals triggered by the natural ligand TRAIL-R1 and TRAIL-R2 trigger at least two distinct
signaling pathways, leading either to death or to NF-kBare also FADD dependent. An essential role for FADD
in TRAIL signaling was further supported by the obser- activation. In this respect, signals induced by TRAIL-R1
and TRAIL-R2 are similar to that induced by TNFR1 andvation that the stable expression of FADD-DN in the B
lymphoma line BJAB rendered these cells insensitive to TRAMP: all four receptors recruit FADD and TRADD
upon overexpression, albeit with different efficiencies.both TRAIL- and FasL-mediated killing (Figure 2D). The
BJAB line expresses both TRAIL-R1 and TRAIL-R2 However, the TRAIL receptors recruit these adaptors
not very efficiently, suggesting that binding may be indi-mRNA (Figure 2C), but only TRAIL-R2 mRNA was de-
tected in TRAIL-sensitive Jurkat cells, which are ren- rect and possibly mediated by yet an additional adaptor
protein. Moreover, the molecular ordering of theadaptordered insensitive to TRAIL by viral and cellular FLIP
(Irmler et al., 1997; Thome et al., 1997). proteins appears to be different. Whereas TRADD is
upstream of FADD in the TNFR1 and TRAMP signaling,These results suggest that FADD is a constituent of
both TRAIL-R1 and TRAIL-R2 signaling complexes. To the converse is observed in the TRAIL-R1 and TRAIL-
R2 signaling pathways. It will be useful to determineanalyze whether a physical association of FADD with the
receptors does indeed occur, Flag-tagged cytoplasmic how this difference influences the receptors' decision
either to activate NF-kB or to initiate the cell deathTRAIL-R1 or TRAIL-R2 were cotransfected with FADD
expression vectors in 293T cells. Immunoprecipitation program.
TRAIL Receptor Signaling
833
Figure 2. TRAIL-R1 and TRAIL-R2 (but Not
TRAIL-R3) Induce Apoptosis That Can Be In-
hibitedby Proteins Competing with FADD Re-
cruitment
(A) DNA fragmentation of 293T cells express-
ing TRAIL-R1, TRAIL-R2, or TRAIL-R3, re-
spectively, was determined by analyzing
cytoplasmic histone-containing DNA com-
plexes. Full-length TRAIL receptors were
transfected alone or in combination with ex-
pression vectors for equine herpes virus E8-
FLIP, human FLIPL, or FADD-DN. Where indi-
cated, 50 mM z-VAD-fmk was added to the
cells 8 hr after the onset of transfection. As
a positive control, TRAMP expression vector
(2 mg) was transfected. Data are the means 6
SEM of triplicate determinations. OD, optical
density.
(B) Apoptosis of 293T cells stably expressing
TRAIL-R1. Parental (wt) and TRAIL-R1±ex-
pressing cells were mock transfected or
transfected with an expression vector for
FADD-DN for 10 hr and then treated with re-
combinant soluble TRAIL (sTRAIL) (solid
bars,500 ng/ml) for 14 hr. Cells were analyzed
by phase contrast microscopy (right, sTRAIL-
treated TRAIL-R1±expressing cells), and the
percentage of apoptotic cells was deter-
mined (left). Controls shown are cells not ex-
posed to sTRAIL (open bars) and treated with
z-VAD-fmk. Data are the means 6 SD of tripli-
cate determinations, each consisting of 150
cells.
(C) Expression of TRAIL-R1 and TRAIL-R2 in
various cell lines. Reverse transcriptase am-
plification of TRAIL-R1, TRAIL-R2, and actin
from RNA of BJAB Burkitt lymphoma, 293T
cells, 293T cells transfected with TRAIL-R1,
and the Jurkat T lymphoma cell line. The con-
trol amplification was done in the absence of
added cDNA.
(D) BJAB cells transfected with dominant
negative FADD (BJAB FADD-DN) or control
transfectants (BJAB wt) were incubated with
soluble FasL (sFasL) or sTRAIL for 16 hr at
the indicated concentrations, and cell sur-
vival was measured by a cell proliferation
assay.
Experimental Procedures into the EcoRI and XhoI site of pCRIII-derived vectors, in frame with
an N-terminal Flag or Myc epitope.
The Flag-TRAIL-R1 expression plasmid (Pan et al., 1997b) wasReagents, Expression Vectors, and Cell Lines
The 293T human embryonic kidney (HEK) cells, BJAB Burkitt lym- kindly provided by V. M. Dixit (University of Michigan Medical
phoma cells, and BJAB cells stably transfected with a dominant School, Ann Arbor, MI) and the Myc-TRADD expression vector was
negative FADD (residues 80±208) (Chinnaiyan et al., 1996) were a gift from D. V. Goeddel (Tularik, San Francisco, CA).
kindly provided by M. Peter (German Cancer Research Center, Hei-
delberg, Germany). For the generation of 293T cells stably express-
Cell Lysis, Coimmunoprecipitation, and Western Blot Analysising TRAIL-R1, a HindIII±BamHI fragment of TRAIL-R1 (Schneider et
For coimmunoprecipitation experiments, 293T cells were trans-al., 1997b) was subcloned into pcDNA3.1/Hygro (1) vector (In-
fected in 10 cm dishes by the calcium phosphate procedure (Sam-Vitrogen). Stable clones were obtained by selection in medium con-
brook et al., 1989) for 8 hr with a total of 10 mg of plasmid. Controltaining 200 mg/ml hygromycin B.
plasmid was added when necessary to keep the total amount ofFlag-tagged recombinant soluble human FasL and TRAIL were
plasmid constant. Thirty to 36 hr after transfection, cells were lysedused as described (Schneider et al., 1997a; Thome et al., 1997).
in 250 ml of lysis buffer (1% Nonidet P-40, 20 mM Tris-HCl [pHMonoclonal antibodies (MAbs) used for immunoprecipitation and
7.4], 150 mM NaCl) supplemented with complete protease inhibitorWestern blotting included an anti-Flag M2 antibody and anti-Flag
cocktail (Boehringer Mannheim). Postnuclear lysates were pre-M2 agarose (Kodak International Biotechnologies), an anti-FADD
cleared for at least 1 hr on Sepharose 6B (Pharmacia) before precipi-antibody (Transduction Laboratories), and an antibody against the
tation for 2 hr or overnight with 3 ml of anti-Flag agarose. PrecipitatesMyc epitope (9E10).
were washed twice with lysis buffer and twice in lysis buffer con-The full-length TRAIL receptors have been described previously
taining 0.1% Nonidet P-40; boiled in sample buffer; and analyzed(Schneider et al., 1997b). The cytoplasmic domains of TRAIL-R1
by SDS±polyacrylamide gel electrophoresis and Western blotting(amino acids 261±465) and TRAIL-R2 (amino acids 232±439) were
onto nitrocellulose (Hybond ECL, Amersham). Blots were saturatedamplified by polymerase chain reaction (PCR) using the proofread-
ing Pwo polymerase (Boehringer, Mannheim) and were subcloned with 5% skim milk, 0.5% Tween-20 in phosphate-buffered saline,
Immunity
834
Figure 3. Interaction of TRAIL-R1and TRAIL-
R2 with FADD and TRADD
(A) (Top) 293T cells were transfected with the
expression vectors coding for the cyto-
plasmic segment of the indicated receptors
and an irrelevant plasmid to keep the total
amount of plasmid constant. Lysates were
immunoprecipitated with anti-Flag antibod-
ies (precipitating the TRAIL receptors), and
the presence of coprecipitating FADD and
TRADD was assessed by Western blot analy-
sis using anti-FADD and anti-Myc antibodies,
respectively. IP, immunoprecipitating. (Bot-
tom) The expression of the transfected pro-
teins in the postnuclear cell extracts.
(B) Analysis as in (A), but using Flag-tagged
full-length TRAIL-R1 to demonstrate the in-
teraction with FADD and TRADD.
and revealed using either anti-Flag MAb at 5 mg/ml, anti-FADD MAb where indicated, at a concentration of 50 mM, 8 hr after transfection.
Thirty-two hours after transfection the extent of cell death was as-at 1 mg/ml, or anti-Myc MAb (9E10) at 2 mg/ml, followed by incuba-
tion with peroxidase-conjugated secondary antibody (Jackson Lab- sessed by morphological inspection of the cells by phase contrast
microscopy, and nuclear DNA degradation was determined in celloratories). Bound antibodies were detected using the enhanced
chemiluminescence kit (Amersham International) according to the lysates using a kit from Boehringer (no. 1544 675) that detects cyto-
plasmic histone-associated DNA fragments.manufacturer's instructions.
BJAB cells (100 ml, 50,000 cells, in 96-well plates) were incubated
at 378C in the presence of soluble FasL or soluble TRAIL at theCell Death and Cell Proliferation Assays
293T cells (2 3 105) (wild-type or stably expressing TRAIL-R1) were indicated concentrations and 1 mg/ml of M2 MAb. After 16 hr, 20
ml of a solution containing 2 mg/ml 3-(4,5-dimethylthiazol-2-yl)-5-transiently transfected in 6 cm plates with 2 mg of pCRIII expression
vector encoding full-length TRAIL-R1, -R2, or -R3, together with (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tertrazolium, inner
salt (MTS) reagent (Promega) and 50 mg/ml phenazine methosulfateexpression vectors for v-FLIP (E8 of EHV-2, 0.5 mg) (Thome et al.,
1997), human FLIPL (0.1 mg) (Irmler et al., 1997), or FADD-DN (2 mg) was added to the cells. Following color development (3 hr), ab-
sorbance at 490 nm was measured with an enzyme-linked immuno-and irrelevant plasmid to keep the total amount of plasmid constant.
Cells were washed and the caspase inhibitor z-VAD-fmk was added, sorbent assay reader.
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